<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01312129</url>
  </required_header>
  <id_info>
    <org_study_id>20-381</org_study_id>
    <nct_id>NCT01312129</nct_id>
  </id_info>
  <brief_title>Effects of Sulfasalazine on BOLD Response to Alcohol Cues</brief_title>
  <official_title>Effects of Sulfasalazine on BOLD Response to Alcohol Cues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Mind Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Mind Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching objective of this pilot study is to apply both neuroimaging and
      pharmacogenetic tools to the study of alcohol dependence. This proposed research will provide
      a mechanistic test of the function of the genetic variation. The specific aims and hypotheses
      are to test whether Sulfasalazine, as compared to placebo, diminishes blood-oxygen-level
      dependent (BOLD) response to alcohol cues in the striatum and prefrontal cortex (PFC). To
      test the hypothesis, we will compare Sulfasalazine treatment with placebo treatment on BOLD
      difference maps for the contrast alcohol minus control. We will also explore whether specific
      genetic variations influence this effect. A double-blind, placebo-controlled 2 (Medication:
      Sulfasalazine 1500 mg vs. placebo control) x 2 (Cue: Alcohol Cue vs. Control cue)
      within-subjects, crossover design will be used to test the hypothesis that Sulfasalazine
      reduces the BOLD response in the striatum and prefrontal cortex after exposure to alcohol
      cues. Twenty alcohol-dependent participants will complete two rounds of the study medication
      followed by an functional magnetic resonance imaging (fMRI) scan, during which they will
      complete an alcohol cue-exposure task. The order of the medication condition will be
      counterbalanced such that subjects will be randomly assigned to receive either Sulfasalazine
      (1500 mg) in the first session and placebo in the second session one week later (or vice
      versa). This pilot study will help to determine whether NMDA receptors play a role in
      cue-elicited activation of key areas of the brain implicated in the development and
      maintenance of substance use disorders. Furthermore, if Sulfasalazine reduces cue-elicited
      activation of these brain regions, as hypothesized; this study will lay the groundwork for a
      larger trial on the efficacy of Sulfasalazine as a treatment for substance use disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overarching objective of this pilot study is to apply both neuroimaging and
      pharmacogenetic tools to the study of alcohol dependence. This proposed research will provide
      a mechanistic test of the function of the genetic variation. The specific aims and hypotheses
      are to test whether Sulfasalazine, as compared to placebo, diminishes blood-oxygen-level
      dependent (BOLD) response to alcohol cues in the striatum and prefrontal cortex (PFC). To
      test the hypothesis, we will compare Sulfasalazine treatment with placebo treatment on BOLD
      difference maps for the contrast alcohol minus control. We will also explore whether specific
      genetic variations influence this effect.

      Several recent studies support the premise that genetic differences may predict treatment
      outcomes. In an early study, an A to G single nucleotide polymorphism (SNP; rs1799971) of the
      mu opiate receptor gene (OPRM1) predicted 12 week abstinence after treatment of alcohol
      dependence with naltrexone (Oslin et al 2003). The relationship was such that individuals
      with at least one copy of the G allele demonstrated lower relapse rates and longer time to
      return to heavy drinking when treated with naltrexone (Oslin et al 2003). These observations
      were recently replicated and extended in the multisite COMBINE study, such that individuals
      with the G allele demonstrated superior outcomes after treatment with naltrexone, in
      combination with medication management (Anton et al 2008). Laboratory studies have suggested
      that clinical effects may be related to a greater reduction in the acute rewarding effects of
      alcohol among individuals with the G allele (Ray &amp; Hutchison 2007) and suggest that the
      mechanism may be related to a blunting of dopamine release in the VTA (Ramchandani et al
      2009). In addition, recent studies with other medications (e.g., topiramate, olanzapine) have
      found that genetic variables predict treatment outcomes (e.g., Hutchison et al 2006;
      Hutchison 2008; Seneviratne et al 2009). It is important to note that these gene by treatment
      interactions are not limited to pharmacological treatments, as recent studies have also
      suggested that genetic variation may predict responses to psychosocial interventions as well
      (Feldstein Ewing et al 2009; Hutchison et al 2006).

      We decided to evaluate the clinical effects of Sulfasalazine because our work to date
      suggests that genetic variations with downstream function implications for glutamate
      function, specifically cysteine/glutamate exchange and glutamate transport, are strongly
      associated with BOLD response in the striatum and prefrontal cortex after exposure to alcohol
      cues. Sulfasalazine is a medication with a well characterized safety profile that has been
      used in the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's
      disease and several types of arthritis, particularly rheumatoid arthritis for many years.
      Most recently, it has been suggested that Sulfasalazine may have beneficial effects in the
      brain, specifically by blocking N-methyl D-aspartate receptor-mediated excitotoxicity
      resulting in reduced neuronal death (Bo Rum Ryu et al, 2003). This pilot study will help to
      determine whether NMDA receptors play a role in cue-elicited activation of key areas of the
      brain implicated in the development and maintenance of substance use disorders. Furthermore,
      if Sulfasalazine reduces cue-elicited activation of these brain regions, as hypothesized;
      this study will lay the groundwork for a larger trial on the efficacy of Sulfasalazine as a
      treatment for substance use disorders.

      To that end, a double-blind, placebo-controlled 2 (Medication: Sulfasalazine 1500 mg vs.
      placebo control) x 2 (Cue: Alcohol Cue vs. Control cue) within-subjects, crossover design
      will be used to test the hypothesis that Sulfasalazine reduces the BOLD response in the
      striatum and prefrontal cortex after exposure to alcohol cues. Twenty alcohol-dependent
      participants will complete two rounds of the study medication followed by an fMRI scan,
      during which they will complete an alcohol cue-exposure task. The order of the medication
      condition will be counterbalanced such that subjects will be randomly assigned to receive
      either Sulfasalazine (1500 mg) in the first session and placebo in the second session one
      week later (or vice versa).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% BOLD Response Increase Above Baseline</measure>
    <time_frame>Over two weeks</time_frame>
    <description>Test whether Sulfasalazine, as compared to placebo, diminishes blood-oxygen-level dependent (BOLD) response to alcohol cues in the striatum and prefrontal cortex (PFC). BOLD response refers to brain activation in response to the presence of oxygen in a particular part of the brain. To test the hypothesis, we will compare Sulfasalazine treatment with placebo treatment. During the fMRI scan session, participants will be presented with the alcohol cue task. We will compare the difference in BOLD response during the presence of alcohol vs. a novel substance during the alcohol cue task. Outcome data collected during the alcohol cue task will provide us with BOLD response data for each intervention period. We will analyze the outcome data using FSL (Oxford Centre for Functional MRI of the Brain (FMRIB) Software - a collection of functional and structural brain image analysis tools).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Sulfasalazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulfasalazine 1500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule x 3 doses 12 hours apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>500mg capsules of Sulfasalazine x 3 doses 12 hours apart.</description>
    <arm_group_label>Sulfasalazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule x 3 doses 12 hours apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-55 years of age with

          -  Alcohol Dependence

        Exclusion Criteria:

          -  Medical or MRI Contraindications

          -  Pregnancy

          -  Allergy to Sulfa medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent E Hutchison, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Mind Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Mind Research Network</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <results_first_submitted>May 30, 2013</results_first_submitted>
  <results_first_submitted_qc>September 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2014</results_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Mind Research Network</investigator_affiliation>
    <investigator_full_name>Kent Hutchison, Ph.D.</investigator_full_name>
    <investigator_title>Professor of Translational Research</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Sulfasalazine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited in Albuquerque, NM between March 2011 and August 2011.</recruitment_details>
      <pre_assignment_details>23 participants were recruited; 10 excluded; 13 approved; 1 participant lost to follow-up; 12 participants completed protocol. Of the 12 participants who completed the protocol, each received both interventions: Sulfasalazine first, then placebo, as well as, Placebo first, then Sulfasalazine. Subjects were randomized to intervention order.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First, Then Sulfasalzine</title>
          <description>Placebo x 3 doses 12 hours apart in the first session, followed by a washout period of 7 days, then Sulfasalazine capsule, 500mg, x 3 doses 12 hours apart in the second session (Sulfasalazine 1500mg total)</description>
        </group>
        <group group_id="P2">
          <title>Sulfasalazine First, Then Placebo</title>
          <description>Sulfasalazine capsule, 500mg, x 3 doses 12 hours apart in the first session (Sulfasalazine 1500mg total) followed by a washout period of 7 days, then Placebo capsule x 3 doses 12 hours apart in the second session.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (24 Hours)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Control Cue</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Alcohol Cue</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (24 Hours)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Control Cue</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Alcohol Cue</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo First, Then Sulfasalazine</title>
          <description>Placebo x 3 doses 12 hours apart in the first session, followed by a washout period of 7 days, then Sulfasalazine capsule, 500mg, x 3 doses 12 hours apart in the second session (Sulfasalazine 1500mg total)</description>
        </group>
        <group group_id="B2">
          <title>Sulfasalazine First, Then Placebo</title>
          <description>Sulfasalazine capsule, 500mg, x 3 doses 12 hours apart in the first session (Sulfasalazine 1500mg total) followed by a washout period of 7 days, then Placebo capsule x 3 doses 12 hours apart in the second session.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>% BOLD Response Increase Above Baseline</title>
        <description>Test whether Sulfasalazine, as compared to placebo, diminishes blood-oxygen-level dependent (BOLD) response to alcohol cues in the striatum and prefrontal cortex (PFC). BOLD response refers to brain activation in response to the presence of oxygen in a particular part of the brain. To test the hypothesis, we will compare Sulfasalazine treatment with placebo treatment. During the fMRI scan session, participants will be presented with the alcohol cue task. We will compare the difference in BOLD response during the presence of alcohol vs. a novel substance during the alcohol cue task. Outcome data collected during the alcohol cue task will provide us with BOLD response data for each intervention period. We will analyze the outcome data using FSL (Oxford Centre for Functional MRI of the Brain (FMRIB) Software – a collection of functional and structural brain image analysis tools).</description>
        <time_frame>Over two weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo x 3 doses 12 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Sulfasalazine</title>
            <description>Sulfasalazine capsule, 500mg, x 3 doses 12 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>% BOLD Response Increase Above Baseline</title>
          <description>Test whether Sulfasalazine, as compared to placebo, diminishes blood-oxygen-level dependent (BOLD) response to alcohol cues in the striatum and prefrontal cortex (PFC). BOLD response refers to brain activation in response to the presence of oxygen in a particular part of the brain. To test the hypothesis, we will compare Sulfasalazine treatment with placebo treatment. During the fMRI scan session, participants will be presented with the alcohol cue task. We will compare the difference in BOLD response during the presence of alcohol vs. a novel substance during the alcohol cue task. Outcome data collected during the alcohol cue task will provide us with BOLD response data for each intervention period. We will analyze the outcome data using FSL (Oxford Centre for Functional MRI of the Brain (FMRIB) Software – a collection of functional and structural brain image analysis tools).</description>
          <units>% BOLD Response increase above baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Control Cue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".106" spread=".140"/>
                    <measurement group_id="O2" value=".082" spread=".156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alcohol Cue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".074" spread=".167"/>
                    <measurement group_id="O2" value=".097" spread=".125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=.05</p_value>
            <p_value_desc>=0.05 is the actual computed p-value via the ANOVA.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>The ANOVA is comparing the % increase in BOLD response above baseline during cue presentation (Alcohol vs. Control) b/w placebo &amp; Sulfasalazine .</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo First, Then Sulfasalazine</title>
          <description>Placebo x 3 doses 12 hours apart in the first session, followed by a washout period of 7 days, then Sulfasalazine capsule, 500mg, x 3 doses 12 hours apart in the second session (Sulfasalazine 1500mg total)</description>
        </group>
        <group group_id="E2">
          <title>Sulfasalazine First, Then Placebo</title>
          <description>Sulfasalazine capsule, 500mg, x 3 doses 12 hours apart in the first session (Sulfasalazine 1500mg total) followed by a washout period of 7 days, then Placebo capsule x 3 doses 12 hours apart in the second session.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kent Hutchison, Ph.D.</name_or_title>
      <organization>The Mind Research Network</organization>
      <phone>720-663-0745</phone>
      <email>khutchison@mrn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

